Methylation Overview by Kendal Stewart, M.D. / Neurotologist & Methylation Expert
The term methylation describes a biochemical process that is utilized in the body for transport of nutrients, energy production and in gene modulation. In patients with decreased methylation activity (i.e. methylation deficiency), there are significant shortcomings in the ability to execute a variety of important chemical functions in the body. These shortcomings can leave the body unprotected from the everyday assault of environmental and infectious agents, sluggish in neurotransmitter production and slow to recover from inflammatory damage. This shortfall can result in a wide range of medical conditions including neurological issues, such as seizures, migraines, dizziness, depression, anxiety, OCD, ADD/ADHD, developmental delay, autism, dementias and memory issues, chronic persistant infections, auto-immune disease, neural tube defects, infertility and pregnancy complications. Appropriate supplementation with the proper methylated vitamins and nutrients will bypass the genetic and acquired deficits and restore appropriate function of the pathway resulting in improvement in these complicated syndromes.
The proper functioning of the methylation cycle is essential for a number of critical reactions in the
body. Consequences of genetic weaknesses (mutations) in this pathway are increased risk factors
leading to a number of serious health conditions. A central pathway in the body that is particularly
amenable to bio-molecular genetic weaknesses is the methionine/folate pathway. There are several
sites in this pathway where blocks can occur as a result of genetic differences. In general, single
biomarkers are identified as indicators for specific disease states. However, it is possible that for a
number of health conditions, including autism and other severe neurological syndromes, it may be
necessary to look at the entire methylation pathway as “a biomarker” for underlying genetic
susceptibility for a disease state. It may require expanding the view of a “biomarker” beyond the
restriction of a mutation in a single gene to a mutation somewhere in an entire pathway of
This does not mean that every individual with mutations in this pathway will have one of the health
conditions listed above. It may be a necessary element, but there may not be a sufficient
environmental or infectious “trigger”. Most health conditions in society today are multifactorial in
nature. In essence, there is an underlying genetically determined risk that requires a significant
infectious or environmental “trigger” to initiate the process. A certain threshold or body burden needs
to be met for each of these factors in order for multifactorial disease to occur. However, part of what
makes the methylation cycle so unique and so critical for our health, is that mutations in this pathway
have the capability to impair all three of these factors. This would suggest that if an individual has
enough mutations or weaknesses in their methylation pathway, it may be sufficient to cause the multifactorial
disease by itself, as methylation cycle mutations can lead to chronic infectious diseases,
increased environmental toxin burdens and have secondary effects on genetic expression.
Methylation Overview by Kendal Stewart M.D. -
Why This Process Is Necessary For Recovery and Health
Dr. Stewart Discusses How The Neuro-Immune Stabilizer Topical Can Help
With Methylation Issues and Support the Pathway With The Appropriate Nutrition
Dr. Stewart Discusses Why Methyl Folate Plus May Be Necessary In Some Cases.
This formula is an Optimal methylation formula with activating co-factor to support the methylation pathway and provide adequate Folinic Acid for those who may be experiencing issues related to a methylation deficiency.
This product is designed to be used in conjunction with the Methylation Complete Melts OR Neuro-Immune Stabilizer Topical Cream that provides the activating co-factors to deliver the additional tetrahydrofolate to support the methylation pathway.
The typical indications for this product include but are not limited to:
*Presence of Folate Receptor Autoantibodies
*Homozygous (2 copies) MTHFR polymorphism
*Increased requirement for development (age 8-20)
*Acute recovery from major neurological injuries
*Recovery from traumatic injuries or sugeries